UNITY Biotechnology, Inc, a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, announced that it will host an in-person and virtual event for investors and analysts on Tuesday, October 15, 2024, at 8:00 a.m. ET in New York, NY. The event will feature presentations from prominent ophthalmology key opinion leaders (KOLs) and company management.
UNITY Biotechnology Ophthalmology Day Agenda
Date: Tuesday, October 15, 2024
Time: 8:00 a.m. until 9:30 a.m. ET
Location: Park Terrace Hotel, New York, NY (with simultaneous webcast)
Registration and Webcast Link: https://lifescievents.com/event/unitybiotechnology/
- Welcome and Introductions: Anirvan Ghosh, Ph.D., Chief Executive Officer, UNITY Biotechnology
- Senolytic Therapeutic Hypothesis: Mike Sapieha, Ph.D., Chief Scientist, UNITY Biotechnology
- UBX1325 Clinical Development Plan – BEHOLD and ASPIRE studies in DME: Robert Bhisitkul, M.D., Ph.D., UCSF School of Medicine
- Retina Expert Roundtable:
- Arshad Khanani, M.D., MA, FASRS, Sierra Eye Associates, University of Nevada Reno School of Medicine
- Dante Pieramici, M.D., California Retina Consultants
- Alicia Tozier, Chief Strategy Officer, UNITY Biotechnology
- Live Q&A
The event will focus on UNITY’s ongoing Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) head-to-head against aflibercept in diabetic macular edema (DME). Twenty-four-week safety and efficacy data are expected in the first quarter of 2025, and 36-week data are expected in the second quarter of 2025. Retina experts will address the evolving therapeutic landscape and the potential of UBX1325 to address unmet needs in DME.
Robert Bhisitkul, M.D., Ph.D.
Robert Bhisitkul, M.D., Ph.D., is an ophthalmologist and retina specialist at UCSF Health who provides medical and laser treatments for macular degeneration, diabetic retinopathy and other retinal diseases. He also performs macular hole and macular pucker surgeries (conditions that cause blurred or distorted vision), retinal detachment and complications of diabetic eye disease. Dr. Bhisitkul recruits patients to participate in UCSF clinical trials of novel therapies for macular degeneration and diabetic retinopathy, and also for studies on long-term outcomes for treatments such as surgically implantable devices that deliver medication. He has published more than 60 papers in clinical and scientific journals.
SOURCE: GlobeNewswire